Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A. Stanczak, Shoib Sarwar Siddiqui, Marcel P. Trefny, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 11, pp. 4912-4923
Open Access | Times Cited: 247

Showing 1-25 of 247 citing articles:

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jérôme Galon, Daniela Bruni
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 3, pp. 197-218
Closed Access | Times Cited: 2614
Harnessing innate immunity in cancer therapy
Olivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature (2019) Vol. 574, Iss. 7776, pp. 45-56
Closed Access | Times Cited: 751
Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
Stefan Mereiter, Meritxell Balmaña, Diana Campos, et al.
Cancer Cell (2019) Vol. 36, Iss. 1, pp. 6-16
Open Access | Times Cited: 424
Small RNAs are modified with N-glycans and displayed on the surface of living cells
Ryan A. Flynn, Kayvon Pedram, Stacy A. Malaker, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3109-3124.e22
Open Access | Times Cited: 397
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Benjamin Smith, Carolyn R. Bertozzi
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 3, pp. 217-243
Open Access | Times Cited: 350
Siglecs as Immune Cell Checkpoints in Disease
Shiteng Duan, James C. Paulson
Annual Review of Immunology (2020) Vol. 38, Iss. 1, pp. 365-395
Open Access | Times Cited: 334
NK Cell-Based Immune Checkpoint Inhibition
Muhammad Khan, Sumbal Arooj, Hua Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 276
Targeted glycan degradation potentiates the anticancer immune response in vivo
Melissa A. Gray, Michal A. Stanczak, Natália Rodrigues Mantuano, et al.
Nature Chemical Biology (2020) Vol. 16, Iss. 12, pp. 1376-1384
Open Access | Times Cited: 260
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis
Heinz Läubli, Lubor Borsig
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 209
Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9
Ernesto Rodríguez, Kelly Boelaars, Kari Brown, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 197
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 194
Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment
Stephanie van de Wall, Kim Santegoets, Eline J.H. van Houtum, et al.
Trends in Immunology (2020) Vol. 41, Iss. 4, pp. 274-285
Closed Access | Times Cited: 157
Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses
Heinz Läubli, Ajit Varki
Cellular and Molecular Life Sciences (2019) Vol. 77, Iss. 4, pp. 593-605
Open Access | Times Cited: 152
Biological Functions and Analytical Strategies of Sialic Acids in Tumor
Xiaoman Zhou, Ganglong Yang, Feng Guan
Cells (2020) Vol. 9, Iss. 2, pp. 273-273
Open Access | Times Cited: 143
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade
Michal A. Stanczak, Natália Rodrigues Mantuano, Nicole Kirchhammer, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 669
Open Access | Times Cited: 122
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
Nicole Kirchhammer, Marcel P. Trefny, Priska Auf der Maur, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Closed Access | Times Cited: 114
Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity
Itziar Ibarlucea-Benitez, Polina Weitzenfeld, Patrick Smith, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 26
Open Access | Times Cited: 105
Design of a mucin-selective protease for targeted degradation of cancer-associated mucins
Kayvon Pedram, D. Judy Shon, Gabrielle S. Tender, et al.
Nature Biotechnology (2023) Vol. 42, Iss. 4, pp. 597-607
Open Access | Times Cited: 47
Diversity of immune checkpoints in cancer immunotherapy
Zhangyan Guo, Rui Zhang, Angang Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 44
Targeting the Siglec–sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma
Philip Schmassmann, Julien Roux, Alicia Buck, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 705
Closed Access | Times Cited: 44
Glycosylation: mechanisms, biological functions and clinical implications
Mengyuan He, Xiangxiang Zhou, Xin Wang
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 33
Glycans as Key Checkpoints of T Cell Activity and Function
Márcia S. Pereira, Inês Alves, Manuel M. Vicente, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 133
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
Simon Wisnovsky, Leonhard Möckl, Stacy A. Malaker, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 5
Open Access | Times Cited: 100
Glycan modification of glioblastoma‐derived extracellular vesicles enhances receptor‐mediated targeting of dendritic cells
Sophie A. Dusoswa, Sophie K. Horrevorts, Martino Ambrosini, et al.
Journal of Extracellular Vesicles (2019) Vol. 8, Iss. 1
Open Access | Times Cited: 94
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Natália Rodrigues Mantuano, Marina Natoli, Alfred Zippelius, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001222-e001222
Open Access | Times Cited: 93
Page 1 - Next Page

Scroll to top